Stockscreener 앱 받기
3.83
5.90%
-0.24
시간 외 거래:
3.75
-0.08
-2.09%
Savara Inc 주식(SVRA)의 최신 뉴스
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Savara Inc. to Participate in Guggenheim Inaugural Healthcare Conference - MyChesCo
Wellington Management Group LLP's Strategic Acquisition in Savar - GuruFocus.com
SVRASavara Inc. Latest Stock News & Market Updates - StockTitan
Savara (NASDAQ:SVRA) Stock Price Down 5.1%Should You Sell? - MarketBeat
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference - StockTitan
Savara Inc. Shines Spotlight on Rare Lung Disease in New TV Feature - MSN
Savara Inc. Rewards New Employees with Inducement Awards - MSN
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV - Business Wire
Savara Announces New Employment Inducement Grant - Business Wire
Savara Inc (NASDAQ:SVRA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Savara Announces New Employment Inducement Grant | SVRA Stock News - StockTitan
Savara Inc (SVRA) deserves deeper analysis - US Post News
Ratio Review: Analyzing Savara Inc (SVRA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Savara Inc (SVRA) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment - MSN
Savara maintains Overweight rating from Piper Sandler on bullish aPAP therapy prospects - Investing.com UK
Savara (NASDAQ:SVRA) Trading Down 3.4%Here's What Happened - MarketBeat
Cantaloupe, Inc. Executives Boost Confidence with Significant Stock Purchases - MyChesCo
Savara stock outlook steady as H.C. Wainwright highlights challenges in doctor engagement at CHEST meeting - Investing.com
Savara (NASDAQ:SVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Should investors be concerned about Savara Inc (SVRA)? - US Post News
The growth track for Savara Inc (SVRA) has changed recently - SETE News
Stock Surge: Savara Inc (SVRA) Closes at 3.82, Marking a 0.26 Increase/Decrease - The Dwinnex
Marshall Wace LLP Has $1.23 Million Stake in Savara Inc (NASDAQ:SVRA) - MarketBeat
Algert Global LLC Boosts Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc. Grants Inducement Awards to New Employee - MSN
Savara Inc. Grants Inducement Awards to New Chief Commercial Officer - MSN
Piper Sandler keeps Overweight rating on Savara shares - Investing.com
FY2025 EPS Estimates for Savara Inc (NASDAQ:SVRA) Reduced by HC Wainwright - MarketBeat
Savara (NASDAQ:SVRA) Trading Down 3.5% - MarketBeat
Savara maintains buy stock rating on aPAP drug potential By Investing.com - Investing.com Australia
Savara maintains buy stock rating on aPAP drug potential - Investing.com
JMP Securities Reiterates “Market Outperform” Rating for Savara (NASDAQ:SVRA) - Defense World
Will Savara Inc (SVRA) beat or miss earnings estimates this quarter? - US Post News
Metric Analysis: Savara Inc (SVRA)’s Key Ratios in the Limelight - The Dwinnex
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting - StockTitan
JMP Securities Reaffirms "Market Outperform" Rating for Savara (NASDAQ:SVRA) - MarketBeat
Savara Inc (NASDAQ:SVRA) Stock Position Increased by XTX Topco Ltd - Defense World
Savara Inc (NASDAQ:SVRA) is Nantahala Capital Management LLC's 9th Largest Position - MarketBeat
Savara shares hold Outperform rating, $15 target on Molbreevi prospects By Investing.com - Investing.com Australia
Savara's SWOT analysis: molgramostim's promise lifts rare disease stock - Investing.com
Savara shares hold Outperform rating, $15 target on Molbreevi prospects - Investing.com India
Savara Inc. Appoints Braden Parker as Chief Commercial Officer - MSN
What is Savara Inc (SVRA) Stock Return on Shareholders’ Capital? - SETE News
Savara's SWOT analysis: molgramostim's promise lifts rare disease stock By Investing.com - Investing.com Canada
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - BioSpace
Frazier Life Sciences Management L.P. Buys 4,157,385 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat
Savara launches early access program for aPAP treatment By Investing.com - Investing.com South Africa
Savara launches early access program for aPAP treatment - Investing.com
4.64%
1.68%
자본화:
|
볼륨(24시간):